Literature DB >> 7887355

Management of diabetic retinopathy.

R P Murphy1.   

Abstract

All persons with diabetes are at risk of retinal complications, although persons with type I (insulin-dependent) diabetes face a greater danger of severe vision loss than persons with type II (noninsulin-dependent) diabetes. Retinopathy has two stages: the nonproliferative stage, which includes intraretinal microaneurysms, hemorrhages, and soft and hard exudates, typically occurs well before the more serious proliferative stage, which is characterized by neovascularization and fibrovascular growth from the retina or optic nerve. Macular edema, a serious development, can occur in either stage. Untreated neovascularization and macular edema are the two major retinal complications that lead to blindness. Good glycemic control has been shown to reduce the development of retinopathy by 76 percent in diabetic patients and to slow progression by 54 percent in those with early retinopathy. Effective hypertension control and diabetic therapy, regular ophthalmologic examinations and properly timed focal laser treatments for macular edema and proliferative retinopathy can markedly reduce the risk of vision loss.

Entities:  

Mesh:

Year:  1995        PMID: 7887355

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  3 in total

1.  Early photocoagulation in patients with either type I or type II diabetes.

Authors:  F Ferris
Journal:  Trans Am Ophthalmol Soc       Date:  1996

Review 2.  Classification of diabetic retinopathy and diabetic macular edema.

Authors:  Lihteh Wu; Priscilla Fernandez-Loaiza; Johanna Sauma; Erick Hernandez-Bogantes; Marissé Masis
Journal:  World J Diabetes       Date:  2013-12-15

3.  Expression of Long Non-Coding RNA (lncRNA) SNHG5 in Patients with Refractory Diabetic Macular Edema and Its Regulatory Mechanism.

Authors:  Junwen He; Zhang Rui; Jing Gao; Yanhong Chen; Yanzi Li; Tao Xu; Shan Wang
Journal:  Med Sci Monit       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.